Intriguingly, CDK4, the binding partner of CDK6, showed no obvious alterations in lenvatinib-resistant cells, which revealed the distinct role of the noncanonical role of CDK6 in the regulation of lenvatinib resistance in HCC cells. This evidence concerns the gene CDK6 and hepatocellular carcinoma.